Tradestie Institutional Equity Comparison Engine

VIR vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while VIR counters with relative strength in Valuation. Fundamentally, VIR trades at 4.3x Forward P/E with -70.2% operating margin (+19582.5% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, VIR sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VIR
VIR 4.3x vs TAK 12.7x Fwd P/E
Growth & Margin Winner TAK
Op Margin -70.2% vs 16.6% ยท YoY +19582.5% vs +6.7%
Momentum & Technical Winner TAK
1Y +78.4% vs +51.8% ยท 52W Pos 49% vs 97%
Options & Structure Winner TAK
BREAKDOWN (6th %ile IV) vs UNCLASSIFIED (5th %ile IV)
VIR NASDAQ
Vir Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.76
-2.01% 1D
Market Cap $2.1B
1M Return -2.01%
1Y Return +78.43%
Forward P/E 4.3x
Unified AI Score
41.6 / 100 SELL
Tech 20.0 Fund 46.0 Flow 67.0 Mom 60.0
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VIR +78.43% TAK +51.79% Spread: +26.64 pp (VIR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
VIR TTM Op. Margin: -70.2% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIR vs TAK. Trailing 12-month operating profitability (VIR -70.2% vs TAK 16.6%) and valuation multiples (VIR 4.3x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VIR (3) vs TAK (7)
Institutional Metric VIR TAK Criterion Row Winner
Market Capitalization Scale $2.1B $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation 4.3x N/M Lower Multiple VIR
Forward P/E Ratio Valuation 4.3x 12.7x Lower Multiple VIR
Revenue Growth (YoY) Growth +19582.5% +6.7% Higher Growth VIR
Operating Margin (TTM) Profitability -70.2% 16.6% Higher Margin TAK
Net Profit Margin Profitability -61.0% 0.9% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency -21.8% 0.6% Higher ROE TAK
52-Week Range Position Momentum 49% ($5โ€“$14) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 1.71ฮฒ ยท 102% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 41.6 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VIR vs TAK Buy Guide
VIR BREAKDOWN
5d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VIR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VIR nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.